By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Esperion Therapeutics, Inc. 

3621 S. State Street
695 KMS Place
Ann Arbor  Michigan  48108  U.S.A.
Phone: 734-332-0506 Fax: 734-332-0516

Esperion Therapeutics, Inc., is a biopharmaceutical company dedicated to the discovery, development and commercialization of a novel class of therapies to treat cardiovascular and metabolic diseases, including atherosclerosis, as they relate to high density lipoprotein cholesterol, "HDL-C", also known as the "good" cholesterol.

The technology platform for Esperion is based upon the Reverse Lipid Transport (RLT) pathway. The RLT pathway is responsible for removing excess cholesterol and other lipids from arterial walls and other tissues for transport to the liver and elimination from the body. The Company's product candidates work by stimulating the RLT pathway through the enhancement of key HDL properties, which may result in improved vascular structure and function. Esperion is focusing its efforts on developing both acute and chronic therapies for cardiovascular and metabolic diseases.

Esperion was founded in 1998 by, among others, members of the Warner-Lambert/Parke-Davis (now Pfizer) team that discovered and developed atorvastatin, the highly successful multibillion-dollar drug. Since that time, an additional group of exceptional scientists and specialists has joined the Company. Many of these individuals have been instrumental in the discovery, development and commercialization of several of the pharmaceutical industry's most successful therapies. It is this combined team that makes Esperion a leading enterprise in HDL drug discovery and research.

Key Management:

  • Roger Newton, Ph.D.
    President and CEO
  • Timothy Mayleben
    Chief Operating Officer and CFO

    Last Updated: 01-18-05

    Key Statistics

    Ownership: Public

    Web Site: Esperion Therapeutics
    Symbol: ESPR

  • Industry

    Company News
    Esperion Therapeutics (ESPR) Prices Public Offering Of Common Stock 3/19/2015 9:30:34 AM
    Esperion Therapeutics (ESPR) Announces Proposed Public Offering Of Common Stock 3/18/2015 8:58:48 AM
    Esperion Therapeutics (ESPR) Announces Positive Top-Line Phase 2b Results For ETC-1002 Added To Stable Statin Therapy In Patients With Hypercholesterolemia 3/17/2015 10:08:51 AM
    Esperion Therapeutics (ESPR) To Present At Bank of America (BAC) Merrill Lynch Smid Cap And Biocentury Future Leaders In The Biotech Industry Conferences 3/13/2015 12:49:55 PM
    Esperion Therapeutics (ESPR) Release: ETC-1002-008 Phase 2b Results To Be Presented At American College of Cardiology 64th Annual Scientific Session 3/9/2015 9:24:25 AM
    Esperion Therapeutics, Inc. (ESPR) Provides ETC-1002 Development Program Update; Reports Fourth Quarter And Full Year 2014 Financial Results 3/6/2015 9:24:11 AM
    Day in the Life of a CEO—Tim Mayleben, Esperion Therapeutics (ESPR) 3/5/2015 8:01:37 PM
    Esperion Therapeutics, Inc. (ESPR) To Present At Barclays Global Healthcare Conference 3/3/2015 2:45:17 PM
    Esperion Therapeutics, Inc. (ESPR) To Provide Fourth Quarter And Full Year ETC-1002 Program Updates And Financial Results 2/27/2015 8:31:14 AM
    EXCLUSIVE: Esperion Therapeutics, Inc. (ESPR) CEO Says FDA Lift Means ETC-1002 Will Be in Phase III Trials By End of 2015 2/3/2015 9:58:17 AM